Abaloparatide
Extensamente estudadoPTHrP Analog | Anabolic Bone-Building Agent
Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP).
Dados moleculares e de pesquisa
- Sequência
- C174H299N56O49 - 41% homology to PTH(1-34), 76% homology to PTHrP(1-34)
- Peso molecular
- 3,960 Da
- Meia-vida
- ~1.7 hours
- Alvos primários
- histamine-h1, pth-receptor
- Vias (pesquisa)
- injectable
- Armazenamento
- Refrigerate pre-filled pen at 2-8°C, do not freeze. Discard after 30 days even if medication remains
Overview
Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor to stimulate new bone formation while minimizing bone resorption. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It was approved in the US in 2017 and EU in 2022 for postmenopausal women and men with osteoporosis at high fracture risk.
Mechanism of action
Abaloparatide works through selective activation of the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor expressed on osteoblasts and osteocytes. It preferentially binds to the RG (relaxed, G-protein-coupled) conformational state of PTH1R, which elicits a transient downstream cyclic AMP signaling response favoring anabolic bone formation over resorption. This selective binding pattern produces more bone-building activity with less hypercalcemic effect compared to native PTH. The result is increased cortical and trabecular bone volume, density, and improved microarchitecture.
Key research findings
- FDA-approved for osteoporosis treatment
- Actively builds new bone (anabolic mechanism)
- Superior hip BMD gains vs teriparatide in trials
- Reduces vertebral fracture risk significantly
- Reduces nonvertebral fracture risk
- Lower hypercalcemia risk than teriparatide
- Works through selective PTH1R activation
- Benefits seen within 6 months
Research applications
Osteoporosis (FDA-Approved)
- Postmenopausal Osteoporosis — FDA-approved for postmenopausal women with osteoporosis at high risk for fracture or who have failed other therapies.
- Male Osteoporosis — FDA-approved for men with osteoporosis at high risk for fracture or intolerant to other treatments.
Bone Health Research
- Fracture Prevention — Phase III trials demonstrated substantial reduction in vertebral and nonvertebral fractures.
- Sequential Therapy — ACTIVExtend trial showed benefits of abaloparatide followed by alendronate for maintained bone protection.
FAQ de Abaloparatide
Why is abaloparatide limited to 2 years of use?+
Cumulative lifetime use is limited to 2 years due to theoretical osteosarcoma risk observed in rodent studies at very high doses. This is a precautionary measure based on animal data, and the ACTIVExtend trial demonstrated that benefits can be maintained by transitioning to alendronate after 18 months of abaloparatide.
Is abaloparatide better than teriparatide (Forteo)?+
Yes. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It also carries lower hypercalcemia risk than teriparatide despite more potent bone-building activity.
What causes the dizziness and palpitations reported with abaloparatide?+
Dizziness, palpitations, and vertigo occur in a subset of users, likely due to transient hypotension or hemodynamic changes from rapid PTH receptor activation. These effects typically subside with continued use as the body adapts. Orthostatic hypotension is a rare but serious warning sign requiring discontinuation.
Can women take abaloparatide if they're still in their reproductive years?+
No. Abaloparatide is teratogenic and contraindicated in pregnancy or potential pregnancy. It's FDA-approved specifically for postmenopausal women and men with osteoporosis, making it appropriate for women beyond reproductive years.
References
- [1]Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE Trial)JAMA
- [2]ACTIVExtend Trial: Abaloparatide Followed by AlendronateMayo Clinic Proceedings
- [3]Phase 2 Dose-finding Study of BA058 in Postmenopausal WomenJournal of Clinical Endocrinology and Metabolism
- [4]Profile of Abaloparatide and Its Potential in Postmenopausal OsteoporosisCureus
Peptídeos relacionados
AHK-Cu
Well studiedHair Growth Copper Peptide | Dermal Papilla Stimulator
Synthetic copper-binding tripeptide targeting dermal papilla cells and hair follicles.
Ara 290
Extensively studiedTissue-Protective Peptide | Innate Repair Receptor Agonist
Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status.
B7-33
Emerging researchRelaxin-2 Analog | Anti-Fibrotic & Cardiovascular
B7-33 is a single-chain peptide analog of human relaxin-2 that selectively activates the relaxin family peptide receptor 1 (RXFP1).
BPC-157
PreclinicalPentadecapeptídeo estudado para reparo de tecidos
BPC-157 é um peptídeo sintético de 15 aminoácidos derivado de uma proteína encontrada no suco gástrico, estudado extensivamente em modelos animais para cicatrização acelerada de tendões, ligamentos, músculos e tecido intestinal.